Frost & Sullivan Recognizes Pharmaco Kinesis Second Year In A Row

LOS ANGELES, CALIFORNIA, March 25, 2014 – For the second year in a row, Frost and Sullivan, a globally recognized growth consulting firm that provides market research and analysis, growth strategy consulting, and corporate training services across multiple industries, announced today that PKC has won its prestigeous “Best Practices Award” for 2014 under their “Global Diagnostic Test Instruments and Biosensors for Life Sciences Company of the Year Award.”

PKC is one of only a handful of companies that have won this award for two years consecutively.

The award recognizes PKC’s continued commitment in the development of advanced technology for the detection, measurement and treatment of various pathogens and viruses that are the source of many major diseases.

Following is the complete press release that was announced today by Frost and Sullivan.

MOUNTAIN VIEW, Calif., March 25, 2014 /PRNewswire/ – Based on its recent analysis of the diagnostic test instruments and biosensors for the food and beverages process and life sciences industry, Frost & Sullivan recognizes Pharmaco Kinesis Corporation with the 2014 Global Frost & Sullivan Company of the Year Award for achieving impressive technological growth in a short span of seven years. The company has become a key enabler of pathogen-testing biosensor solutions for the entire value chain in the process industry and in the key testing space of the life-sciences market.

Pharmaco Kinesis’ top-quality and innovative biosensor kits are employed across a wide range of sectors, including processing

2014 F&S Award

industry, research laboratories, defense, and medical-diagnostics facilities. The company achieved this remarkable growth by establishing the largest partner network through collaborations with leading companies. Further, its researchers develop highly capable, scalable, and secure sets of product offerings for different types of end-user applications and product specifications (both large and small) with a clear, phased roadmap for planned application growth.

Pharmaco Kinesis has excelled in transforming its innovation expertise into exceptional business value, as evidenced by its efficient delivery of E. coli detectors (biosensors), metronomic biofeedback pumps (MBP) and smart-brain retractors (SBR). Apart from providing services and solutions, it also successfully meets research and medical-test market needs across the globe.

Dr. Rajender Thusu
Industry Principal &
Sensors & Instrumentation
(M&I Practice)

“The ability to stay flexible in its operative domain and redirect strategic paths from time to time, according to specific customer requirements, gives the company an edge in the competitive market,” said Frost & Sullivan Industry Principal Dr. Rajender Thusu. “By utilizing its promising technology platform, swift response to customer demands, problem-resolving capacity, and significant innovations to solution portfolios, the company has ensured impressive customer satisfaction and growth.”

The success of Pharmaco Kinesis’ strategic execution capabilities is evident in the continued adoption of its different platforms by leading brands within the pharmaceuticals and process industries. A wide distribution network, wherein Pharmaco Kinesis allows channel partners to deploy its health solutions among their customer bases, is another reason the company has enjoyed sizeable adoption rates.

To ensure enhanced product and service value, Pharmaco Kinesis provides the most comprehensive set of capabilities and continuously refines its go-to-market strategy to keep pace with the rapid evolution of the test market and its changing demands. It has particularly stood out for its quality-assured biosensors for pathogen detection for tier one industrial customers.

“Pharmaco Kinesis’ successful development of an extremely sensitive electrochemical impedance spectroscopy-based biosensor footprint has given the company tremendous credibility, as it is the only company to have done so,” observed Thusu. “The basis of Pharmaco Kinesis’ innovation is its inventive technology platform, developed individually and tested with other allied-user partners.”

Frost & Sullivan research shows the company understands diverse customer needs and accordingly strategizes moves for all-inclusive growth, which has gone a long way in improving customer satisfaction. Further, it services not only the user of the test module, but the entire channel. The company also ensures comprehensive reporting and feedback to help users frequently fine-tune their lead MBP product and solution offerings.

Pharmaco Kinesis has primarily focused on penetrating the food-processing industry (meats, dairy and dairy products, and eggs) with its electrolyte-insulator-semiconductor (EIS)-based biosensor test platform. The product also displays growth potential in other application areas, including patient-care monitoring, biodefense, environmental monitoring, and infection control. Its unwavering focus on tracking emerging customer needs enables it to launch industry-first products and solutions designed to offer superior customer value and returns on investment.

Pressing ahead with its best-in-class approach, the company also developed a prototype for a continuous monitoring system, which not only constantly monitors, but also predicts testing requirements for E.Coli pathogens in meats, poultry and dairy product batches that are to be processed in a plant. Additionally, Pharmaco Kinesis has distinguished itself by delivering innovative next-generation test and tracking solutions that are nano-sized, greatly scalable and accurate, and extremely rapid.

“Be it onboard biofeedback; smart-drug delivery systems; simple and smart, solid-state biosensors; or an intelligent interbody fusion device, Pharmaco Kinesis has proved its ability to consistently innovate and grow,” noted Thusu.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Frost and Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

This news release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the management of Pharmaco-Kinesis Corporation and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.